Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
ID: 344644Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344644

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-256.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" aimed at developing evidence-based interventions to address cancer-related health disparities among diverse populations in the United States. This initiative utilizes a phased cooperative agreement mechanism (UG3/UH3), where the initial UG3 phase focuses on refining cancer-related interventions and preparing for a pragmatic trial, followed by the UH3 phase to conduct the trial and assess its effectiveness on various cancer-related outcomes. Interested applicants, including a wide range of eligible organizations such as historically black colleges, tribal governments, and community-based organizations, must submit their applications through Grants.gov by November 17, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-22-256.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), is issuing an opportunity under the Pragmatic Trials across the Cancer Control Continuum program. This funding aims to develop evidence-based interventions focused on overcoming cancer-related health disparities among diverse U.S. populations. The funding mechanism is a cooperative agreement (UG3/UH3) structured in two phases: an initial UG3 phase to refine interventions and prepare for a pragmatic trial, followed by a UH3 phase to conduct the trial itself. Applications must highlight the proposed intervention’s significance, innovation, and the investigator team's qualifications. The ultimate goal is to assess the intervention's effectiveness on various cancer-related outcomes using pragmatic trial designs that reflect real-world settings. The application process involves adherence to strict guidelines and the submission of material through Grants.gov. Successful applications are expected to demonstrate strategic plans and measurable milestones to ensure effective progress and implementation of research.
    Similar Opportunities
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)" aimed at fostering long-term partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). This initiative seeks to enhance cancer research by addressing disparities in cancer outcomes and promoting outreach and engagement across diverse populations. The program anticipates awarding approximately 12 cooperative agreements, with a minimum funding amount of $850,000, and key deadlines include an estimated synopsis close date of January 16, 2026, and an expected award date of September 1, 2026. For further inquiries, interested applicants can contact Dr. Sandra San Miguel-Majors at 240-276-5977 or via email at ncicpachU54@mail.nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant to enhance cancer screening and preventive services for populations experiencing health disparities. This initiative aims to address barriers to cancer care by developing interventions that operate at multiple levels, including patient, clinician, healthcare settings, and community factors, while encouraging collaboration with community partners. The funding reflects NIH's commitment to advancing health equity, particularly for historically underserved groups, and requires applicants to submit a Plan for Enhancing Diverse Perspectives. Interested applicants can find more information and guidelines at the provided link, with applications due by January 7, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)" aimed at investigating the biological and genetic mechanisms underlying cancer health disparities among diverse racial and ethnic populations. This funding initiative encourages innovative pilot studies that focus on identifying cancer risk factors, developing preventative strategies, and enhancing research methodologies, while fostering a multidisciplinary cohort dedicated to cancer health disparities research. Eligible applicants include a wide range of entities such as educational institutions, nonprofits, and tribal organizations, with a maximum funding amount of $275,000 available for a two-year project period. Interested parties should note that the application deadline is November 16, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-244.html for further details.
    Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Basic Research in Cancer Health Disparities grant, aimed at supporting innovative research into the biological and genetic causes of cancer health disparities among diverse racial and ethnic populations. This grant encourages applications from a wide range of eligible applicants, including higher education institutions, nonprofits, and organizations serving underrepresented groups, with a focus on mechanistic studies, new methodologies, and the use of biospecimens to uncover cancer risk factors and develop prevention strategies. The application process opens on January 5, 2025, with the first submission deadline on February 5, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-243.html.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.